Crohn's News Blog

Weblog – Informação sobre DII

Archive for the ‘Health’ Category

Humira most favored among biologics for Crohn’s disease and ulcerative colitis

leave a comment »

Health | Crohn’s disease | Humira

Abbott/Eisai’s Humira most favored among biologics for Crohn’s disease and ulcerative colitis, says DR report

US gastroenterologists survey by USA-based advisory firm Decision Resources estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn’s disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe’s Remicade (infliximab) by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai’s Humira (adalimumab) will increase to 36%. Surveyed gastroenterologists also indicate that the percentage of patients treated with a biologic who receive UCB/Otsuka’s Cimzia (certolizumab pegol) will rise from 9% to 12% within the next year.

DR’s new Physician & Payer Forum report, titled The Expanding Biologics Landscape in CD and UC: Clinician and Payer Perspective on the Role of Premium-Priced Biologics in CD and UC Treatment also finds that, on average, surveyed gastroenterologists report prescribing Remicade to 31% of their ulcerative colitis patients.

Alcohol kills more than AIDS, TB or violence: WHO

leave a comment »


Alcohol causes nearly 4 percent of deaths worldwide, more than AIDS, tuberculosis or violence, the World Health Organization warned on Friday.

Rising incomes have triggered more drinking in heavily populated countries in Africa and Asia, including India and South Africa, and binge drinking is a problem in many developed countries, the United Nations agency said.

Yet alcohol control policies are weak and remain a low priority for most governments despite drinking’s heavy toll on society from road accidents, violence, disease, child neglect and job absenteeism, it said.

Approximately 2.5 million people die each year from alcohol related causes, the WHO said in its “Global Status Report on Alcohol and Health.”

“The harmful use of alcohol is especially fatal for younger age groups and alcohol is the world’s leading risk factor for death among males aged 15-59,” the report found.
Leia o resto deste artigo »

Written by CarlAn

11/02/2011 at 18:54

H1N1 survivors have ‘super’ immunity

leave a comment »

Written by CarlAn

15/01/2011 at 21:23

What’s behind Humira’s bullish forecast?

with 2 comments

What’s behind Humira’s bullish forecast?

A report predicting that Humira will become the world’s biggest product in two years’ time generated positive news for the Abbott Labs/Eisai arthritis drug. Several factors are driving the bullish forecast.

While growth is by no means a given, analysts are actually optimistic about the entire class of biologics called TNF inhibitors, which are often used to treat rheumatic diseases, like rheumatoid arthritis (RA), ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis. According to the forecast, by EvaluatePharma, Humira will become the top-selling anti-TNF—and the world’s biggest product—in 2012 with global sales of $8.3 billion and will retain its top spot until 2016, when sales could exceed $10 billion. Anti-TNF drugs from Pfizer/Amgen (Enbrel) and Johnson & Johnson/Merck (Remicade) will reach the no. 3 and no. 7 spots on the top-10 list, the forecast noted.

Jeffrey Stewart, who heads up Abbott’s US Humira business, summed up the reasons why analysts are keen on these drugs. “The unmet need is great, the therapeutic gain and net value is very significant vs. the standard of care, and a significant number of patients [for whom anti-TNF drugs are indicated] still have not been put on these medications,” said Stewart, who is divisional VP for immunology, in Abbott’s pharmaceutical products division.

Read More…»»What’s behind Humira’s bullish forecast?


Powered by ScribeFire.

Written by CarlAn

06/05/2010 at 17:09

New Studies Presented at Digestive Disease Week Highlight the Value of PillCam(R) Capsule Endoscopy

with 2 comments

More Than 68 PillCam(R) SB and PillCam(R) ESO Studies Presented; Company to Host Conference Call on May 7 at 1:00pm ET to Review DDW Abstract Highlights

Given Imaging Ltd. today announced that new studies confirmed the value of using PillCam(R) SB more frequently and earlier in the diagnostic algorithm in a range of disease states, including anemia, confirmed or clinically suspected Crohn’s disease, upper gastrointestinal bleeding and occult or obscure gastrointestinal bleeding (OGIB).

The studies concluded that PillCam SB is able to accelerate the time to diagnosing these conditions and often can obviate the need for additional diagnostic tests. Additional studies showed the value of PillCam(R) ESO as an emergency room tool to expedite triaging of patients presenting with upper gastrointestinal bleeding (UGIB) or non-cardiac chest pain. More than 68 studies were presented on PIllCam SB and PillCam ESO at the Digestive Disease Week(R) (DDW) 2010 conference concluding today in New Orleans.

NEW ORLEANS, LA, May 05, 2010 (COMTEX)
Given Imaging Ltd. /quotes/comstock/15*!givn/quotes/nls/givn (GIVN
20.10, -0.75, -3.60%)

Read More…

, ,

Powered by ScribeFire.

Written by CarlAn

06/05/2010 at 00:08

Study finds sharp rise in colitis among children

with one comment

Study finds sharp rise in colitis among children


NEW YORK (Reuters Health) – A study of Northern California children finds that diagnoses of the digestive disease ulcerative colitis increased nearly three-fold between 1996 and 2006 — for reasons that are not yet clear.

Ulcerative colitis is one of the two major forms of inflammatory bowel disease (IBD), a group of conditions marked by chronic inflammation in the intestines, leading to symptoms like abdominal pain and diarrhea. The other major form is Crohn’s disease.

It’s estimated that about 1 million Americans have IBD. However, when it comes to children, relatively little has been known about the epidemiology of IBD — including its incidence rate and how that rate may be changing over time.

Leia o resto deste artigo »

Written by CarlAn

28/04/2010 at 23:52

Acne drug linked to bowel disease

with one comment

Acne drug linked to bowel disease

Individuals receiving the acne drug isotretinoin are four times more likely to develop a bowel disease known as ulcerative colitis within a year of consumption.

Isotretinoin, best known by the brand-name Accutane, is commonly used for the treatment of severe recalcitrant acne. Serious side effects such as suicidal tendencies and liver damage are reported following the use of the drug.

Certain associations of the drug and inflammatory bowel disease (IBD) — a group of inflammatory disorders of the gastrointestinal tract, including ulcerative colitis and Crohn’s disease — had already been reported; the definite association, however, has yet to be confirmed.

Leia o resto deste artigo »

Written by CarlAn

11/04/2010 at 16:41

%d bloggers like this: